{"schema_version":"secwatch.filing_event.v1","accession":"0001420800-22-000020","form_type":"8-K","ticker":"ENOV","cik":"0001420800","company_name":"Enovis CORP","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.596941+00:00","generated_at":"2026-06-22T13:12:30.547181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enovis Q3 revenue $384M (+7% organic), adj EPS $0.59 (+34% YoY), guides FY adj EPS $2.20-$2.25","bullets":["Reconstructive segment revenue $127M (+15% organic); Prevention & Recovery $257M (+4% organic).","Reported net loss from continuing ops $(66)M ($(1.22)/diluted share); adjusted EPS grew to $0.59.","Adjusted EBITDA $57M (14.9% of sales); core margins improved 40 bps despite inflation.","FY 2022 outlook: organic growth ~6.5%, total sales growth ~10%, adj. EBITDA $235-$240M.","Launched EMPOWR 3D Knee in Europe and two connected bracing products for Motion iQ platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001420800-22-000020","json":"https://secwatch.observer/filing/0001420800-22-000020.json","markdown":"https://secwatch.observer/filing/0001420800-22-000020.md","text":"https://secwatch.observer/filing/0001420800-22-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420800/000142080022000020/0001420800-22-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420800/000142080022000020/cfx-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:12:30.547181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6b3a9f5073801b98c0a4eb6c23854bfe8d1d378","claim":"Enovis CORP reported third quarter 2022 results: revenue $384 million, net income $(66) million, EPS $(1.22) per diluted share.","evidence_excerpt":"Enovis’ third quarter net sales of $384 million were 7% higher than the prior year third quarter on both reported and organic bases. Enovis Reconstructive segment revenue of $127 million reflected 15% organic growth, and its Prevention and Recovery segment revenue of $257 million reflected 4% organic growth. The Company reported third quarter 2022 net loss from continuing operations of $(66) million, or $(1.22) per diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420800/000142080022000020/0001420800-22-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2022"},{"label":"Revenue","value":"$384 million"},{"label":"Net income","value":"$(66) million"},{"label":"EPS","value":"$(1.22) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}